Lanreotide vs Octreotide
Overview
Lanreotide and Octreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Lanreotide and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Octreotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | every 4 weeks | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Octreotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Lanreotide: FDA-approved. Octreotide: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Octreotide?
- Lanreotide and Octreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Lanreotide is FDA-approved for one or more indications, whereas Octreotide is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take Lanreotide and Octreotide together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Octreotide FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Octreotide is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references